Hands with red spots on light blue background showing Atopic Dermatitis

Why is Aclaris Therapeutics Stock Trading Lower on Monday?

Aclaris Therapeutics Inc. (NASDAQ:ACRS) CEO Neal Walker affirmed on Monday that the clinical-stage biopharmaceutical company will maintain its core development priorities despite missing primary and secondary endpoints in a Phase 2 atopic dermatitis study.

Walker emphasized that Aclaris remains committed to advancing its oral kinase inhibitors and bispecific antibody programs toward major clinical and regulatory milestones throughout 2027.

Bosakitug Misses Endpoints But Shows Target Engagement

Aclaris reported topline data from the Phase 2 ADMIRATION trial evaluating bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, in patients with moderate-to-severe atopic dermatitis.

Although the study failed to meet its primary or secondary efficacy goals, patients generally tolerated the treatment well.

Pharmacodynamic data also revealed strong TSLP target engagement alongside the downregulation of key immune activation biomarkers, including Th1, Th2, and Th17.

Aclaris Launches Phase 2b Modzatinib Trial

Alongside the readout, Aclaris initiated its Phase 2b ALPHA trial of modzatinib (ATI-2138) for moderate-to-severe lichen planus (LP).

LP is a chronic inflammatory, autoimmune condition that causes an immune system attack against cells in the skin, hair, nails, and mucous membranes. It causes painful oral erosions, genital lesions, permanent scarring, and hair loss, while oral LP carries a malignancy risk.

The U.S. Food and Drug Administration previously granted Fast Track Designation to modzatinib for this chronic, CD8 cytotoxic T cell-driven inflammatory disease.

The ALPHA study will evaluate two dose levels of modzatinib against a placebo in roughly 100 participants whose biopsy-proven disease resists topical therapies. Researchers will enroll patients with oral erosive LP in the initial cohort.

Dual Mechanism And Upcoming Pipeline Milestones

Modzatinib, a potential first-in-class oral therapy, inhibits both ITK and JAK3 to disrupt LP pathology at two points.

ITK inhibition blocks upstream T-cell receptor signaling to reduce T-cell activation, cytotoxicity, and inflammatory cytokines, while JAK3 inhibition blocks downstream cytokine signaling to curb T-cell proliferation and survival.

CEO Walker noted that Aclaris also completed IND-enabling studies for its oral ITK inhibitor ATI-9494 and plans to submit the IND this quarter.

Additionally, the company aims to launch a Phase 2b trial of its anti-TSLP/IL-4Rα bispecific antibody, ATI-052, in eosinophilic esophagitis during the first quarter of 2027.

ACRS Price Action: Aclaris Therapeutics shares were down 13.52% at $3.39 during premarket trading on Monday, according to Benzinga Pro data.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs